Azelaic Acid 10% vs 15% vs 20%: Which Is Better?

Azelaic acid 10% vs 15% vs 20% is a choice about evidence, formulation, access, and your pigment problem. For a direct-retail cosmetic, 10% is accessible but has thin clinical evidence. A 15% gel has placebo-controlled evidence for post-acne marks, while 20% cream has the deepest trial record for melasma and facial hyperpigmentation. No clean trial proves that a standard 20% product beats matched 15% or 10% products.

Azelaic acid 10% vs 15% vs 20% at a glance

The useful verdict is narrower than “stronger works better.” Ten percent fits someone seeking a cosmetic option without a prescription, while accepting weaker evidence. Fifteen percent is worth discussing when acne marks coexist with acne or rosacea. Twenty percent has the clearest clinical case for a prescriber considering melasma or facial hyperpigmentation. In the US and UK, pigmentation is not an approved label indication for the prescription products discussed here.

What changes when the azelaic acid percentage changes

Decision point	10%	15%	20%
Best evidence-based fit	Direct-retail cosmetic for the look of uneven tone	Post-acne marks, with clinician input where prescription-only	Melasma or facial hyperpigmentation under clinician care
Pigmentation evidence	Limited and confounded by multi-ingredient formulas	One 12-week placebo-controlled PIH trial, plus smaller earlier work	Several 24-week melasma and facial-pigmentation trials
Form commonly studied	No single standard cosmetic vehicle	Gel	Cream
Time tested	No reliable single-ingredient timeline established	12 weeks for acne-related PIH	24 weeks in key pigmentation trials
Access checked 8 November 2026	UK direct-retail cosmetic exists	Prescription medicine in the US and UK	Prescription medicine in the US and UK
Local irritation	Possible; no comparable prescription trial dataset	Burning, stinging, itching, or dryness can occur	Burning, stinging, itching, or dryness can occur
Main limit	Retail availability is not proof of melasma treatment	Less melasma evidence than 20% cream	More evidence does not prove superiority over matched lower strengths

The percentages describe different finished products, since a 15% gel and a 20% cream differ in vehicle and inactive ingredients. That changes spread, delivery, and tolerability, so you cannot treat the label number like a dose-response chart.

No fair strength-versus-strength trial settles this

King and colleagues reviewed 43 randomized trials in the 2023 Journal of Cosmetic Dermatology. The seven melasma trials tested 20% azelaic acid, not 10% against 15% against 20%. The review found 20% better than vehicle for melasma, but did not establish that concentration alone caused a better result.

Mazurek and Pierzchała's 2016 study assigned 60 women with melasma to three azelaic acid products for 24 weeks. The products contained 5%, 10%, or 20% azelaic acid, with only 20 women per group. The 20% product reduced pigment most, but it also contained mandelic acid, phytic acid, 4-n-butylresorcinol, and ferulic acid. That study compares formulas, not percentages.

This distinction matters. A 10% cosmetic is neither a diluted prescription gel nor interchangeable with nanocrystal hydrogels tested in acne research. For the ingredient's wider uses, see the azelaic acid evidence guide.

What 15% and 20% actually did for pigmentation

Shucheng and colleagues' 2024 randomized, double-blind trial enrolled 72 people with mild to moderate acne, and 60 finished. Most had Fitzpatrick type III skin, and all were aged 18 to 33. After 12 weeks, the 15% gel group had a greater fall in measured melanin within post-inflammatory hyperpigmentation than placebo.

That supports post-acne marks, but not melasma or superiority over another strength. It is still one young, single-centre population, and the trial was registered retrospectively. Our guide to post-inflammatory hyperpigmentation in darker skin explains why stopping new inflammation matters alongside fading old marks.

For 20%, Lowe and colleagues tested a cream against its vehicle for 24 weeks in 52 people with phototypes IV to VI. Investigator ratings and chromometer readings favoured azelaic acid, while burning and stinging occurred more often than with vehicle at some visits.

Melasma evidence also centres on 20% cream: Baliña and Graupe studied 329 women for 24 weeks, with sunscreen in both groups. Azelaic acid gave 65% good or excellent results without beating 4% hydroquinone on the main comparisons, supporting activity rather than superiority.

Expect a 12-to-24-week decision window

The trial timelines make two weeks too early for a fair verdict. The 15% PIH trial assessed its main result at 12 weeks. The stronger 20% pigmentation evidence usually ran for 24 weeks. Pigment may fade slowly even after the trigger stops, as our hyperpigmentation timeline explains.

If you track progress, compare photos taken with the same camera, distance, angle, and light. A brighter bathroom or different exposure can mimic fading. Photos can record appearance, but they cannot confirm melasma or measure treatment response clinically.

Do not increase a prescription strength or switch products from photos alone. If a prescriber chose the treatment, they should interpret progress and irritation. For a cosmetic, follow its label and seek advice if irritation persists.

Irritation can erase the advantage of a higher percentage

Both prescription labels list local burning, stinging, itching, dryness, or redness. The US 15% label recorded burning, stinging, or tingling in 29% of rosacea-trial participants. The US 20% label recorded its most common reactions in about 1% to 5% of acne-trial participants. Those numbers do not show that 15% is harsher. The conditions, vehicles, studies, and participants differed.

Persistent inflammation can leave more pigment, especially in darker skin. Get advice for severe or lasting irritation, swelling, breathing symptoms, or abnormal skin lightening. Keep azelaic acid away from eyes and mucous membranes.

Pregnancy wording also differs by country and product. Current UK labels for 15% gel and 20% cream say controlled pregnancy studies are lacking and advise caution. The US 20% label says it should be used during pregnancy only if clearly needed. The US 15% label reports minimal systemic absorption and says fetal exposure is not expected. Pregnancy, trying to conceive, and breastfeeding still warrant a clinician or pharmacist check.

Preventing the pigment from returning matters more than five percentage points

Azelaic acid cannot remove the trigger for every dark mark. Acne-related PIH keeps forming if acne stays inflamed. Melasma often relapses with ultraviolet and visible-light exposure.

Passeron and colleagues' 2026 global consensus treats photoprotection as part of treatment and maintenance. It recommends broad-spectrum UVB and UVA protection for pigment disorders. For melasma and PIH, it also favours protection from high-energy visible light, often through tinted products with pigments such as iron oxides.

That does not make phone screens the main target. The consensus cites a one-week study using maximum device blue light for eight hours daily. Melasma did not worsen, but long-term effects remain uncertain. The screen intensity was 100 to 1,000 times lower than sunlight. Our guide to why melasma returns in summer covers the relapse pattern and practical photoprotection.

How to make the choice

Start with the pigment type, not the percentage. A flat mark left by acne is a different problem from symmetrical melasma or a changing sun spot. If the diagnosis is unclear, a dermatologist should make that call before you chase strength.

• Choose the 10% route only as a cosmetic decision, with realistic evidence expectations.
• Discuss 15% when post-acne marks sit alongside acne or rosacea and a prescription is appropriate.
• Discuss 20% when melasma or broader facial hyperpigmentation is the concern and stronger trial support matters.
• Let the prescriber choose, continue, stop, or switch any prescription product.

A professional should also decide when pigmentation changes quickly, becomes irregular, or fails to improve across the trial-length window. The percentage cannot fix a wrong diagnosis. Nor can it compensate for a formula your skin cannot tolerate.